An experimental drug combination that inhibits an enzyme that’s abundant in tumor cells shows promise against several cancers, new research finds.
Malignant cells produce excess telomerase, an enzyme that may play a role in keeping them alive, says biochemist Calvin B. Harley of Geron Corp. in Menlo Park, Calif.
Log in
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.